Therapeutic targeting of CD95 and the TRAIL death receptors

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 3, 2011, Pages 294-310

  Gerspach, Jeannette ^a   Pfizenmaier, Klaus ^a   Wajant, Harald ^b  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Agonistic antibody; Cancer therapy; Caspase 8; CD95 Fas; CD95l; Death receptors; ScFv; TRAIL; TRAILR1 DR4; TRAILR2 DR5

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CONATUMUMAB; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DROZITUMAB; DULANERMIN; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GANITUMAB; GEMCITABINE; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; RITUXIMAB; SORAFENIB; TIGATUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL DEATH; CHEMOSENSITIVITY; CHONDROSARCOMA; COLON CANCER; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG TARGETING; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RECTUM CANCER; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80052328685     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211796957739     Document Type: Review

References (165)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487-501.
2. Fesik SW. Insights into programmed cell death through structural biology. Cell 2000; 103: 273-282.
3. Wajant H. Death receptors. Essays Biochem 2003, 39: 53-71.
4. Chan FK. Three is better than one: Pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007; 37: 101-107.
5. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene 2003; 22: 7070-7077.
6. Schütze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 2008; 9: 655-662.
7. Salvesen GS, Riedl SJ. Caspase mechanisms. Adv Exp Med Biol 2008; 615: 13-23.
8. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol 2009; 21: 871-877.
9. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185-193.
10. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
11. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
12. Chen DJ, Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009; 20: 646-658.
13. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-1361.
14. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 161-169.
15. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008; 118: 111-123.
16. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118: 100-110.
17. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998; 187: 1825-1838.
18. Peng SL, Robert ME, Hayday AC, Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 1996; 184: 1149-1154.
19. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998; 9: 47-57.
20. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Moroy T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 1995; 10: 2397-2401.
21. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413.
22. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
23. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325-331.
24. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8: 395-403.
25. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 14: 607-623.
26. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-851.
27. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigendirected activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20: 4101-4106.
28. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge l, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-2212.
29. Gerspach J, Wajant H, Pfizenmaier K. Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 2009; 49: 241-273.
30. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15: 751-761.
31. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, et al. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007; 139: 568-577.
32. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcγ receptor-dependent mechanism drives antibodymediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19: 101-113.
33. Koschny R, Walczak H, Ganten TM. The promise of TRAIL-- potential and risks of a novel anticancer therapy. J Mol Med 2007; 85: 923-935.
34. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
35. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567.
36. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
37. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2640-2646.
38. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64: 8502-8506.
39. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003; 17: 94-96.
40. Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, Macfarlane M, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007; 46: 1498-1508.
41. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005; 42: 588-597.
42. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, et al. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistancemediating block of effector caspase maturation. Mol Cell Biol 2003; 23: 777-790.
43. Ashkenazi, A.J., Kelley, R.F., O'Connel, M.T., Pitti, R.M., Schwall, R.H. Apo-2 ligand. EP2017341 (2009).
44. Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, et al. A unique zinc-binding site revealed by a highresolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633-640.
45. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Roder C, et al. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 2010; 88: 729-740.
46. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-38.
47. Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J, et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. ASCO Annual meeting abstract. J Clin Oncol 2007; 25: 8078.
48. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, et al. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. ASCO Annual meeting abstract. J Clin Oncol 2009; 27: 4129.
49. Soria J-C, Smit E, Khayat D, Besse B, Yang X, Hsu C-P, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small cell lung cancer. J Clin Oncol 2010; 28: 1527-1533.
50. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. ASCO Annual meeting abstract. J Clin Oncol 2006; 24s: 3013.
51. Ashkenazi, A.J., Chuntharapai, A., Kim, K.J. Monoclonal antibodies, cross-reactive antibodies and method for producing the same. EP2058334 (2009).
52. Adams, C.W., Ashkenazi, A.J., Chuntharapai, A., Kim, K.J. Treatment of cancer using anti-Apo-2 antibodies. US7595046 (2009).
53. Zhou, T., Kimberly, R.P., Koopman, W.J., LoBuglio, A.F., Buchsbaum, D.J. Antibody selective for DR4 and uses thereof. US20090208483 (2009).
54. Zhou, T., Ichikawa, K., Kimberly, R.P., Koopman L, Ohsumi, J. W.J., LoBuglio, A.F., Buchsbaum, D.J. Combinations of antibodies selective for DR5 and other therapeutic agents. US7704502 (2010).
55. Salcedo, T.W., Ruben, S.M., Rosen, C.A., Albert V.R., Dobson, C., Vaughan, T. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors. US7361341 (2008).
56. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16: 5734-5749.
57. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773-782.
58. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor- 1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
59. Wiezorek J, Holland P, Graves, J. Death receptor agonists as a targeted therapy for Cancer. Clin Cancer Res 16: 1701-1708.
60. Saleh MN, Percent I, Wood TE, Posey J, III, Shah J, Carlisle R, et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. ASCO Annual meeting abstract. J Clin Oncol 2008; 26:3537.
61. LoRusso P, Hong D, Heath E, Kurzrock R, Wang D, Hsu L, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor- 2 agonist, in adult patients with advanced solid tumors. ASCO Annual meeting abstract. J Clin Oncol 2007; 25:3534.
62. Paz-Ares L, Sánchez Torres M, Diaz-Padilla I, Links M, Reguart N, Boyer M, et al. Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced nonsmall cell lung cancer (NSCLC). ASCO Annual meeting abstract. J Clin Oncol 2009; 27: 19048.
63. Rougier P, Infante J, Van Laethem J, Stephenson J, Uronis H, Schwartzberg L, et al. A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC):Safety results. ASCO Annual meeting abstract. J Clin Oncol 2009; 27: 4130.
64. Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin M, Hsu M, et al. A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). ASCO Annual meeting abstract. J Clin Oncol 2009; 27: 4501.
65. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
66. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-1756.
67. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
68. Nishimura Y, Hirabayashi Y, Matsuzaki Y, Musette P, Ishii A, Nakauchi H, et al. In vivo analysis of Fas antigen-mediated apoptosis: Effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997; 9: 307-316.
69. Nishimura-Morita Y, Nose M, Inoue T, Yonehara S. Amelioration of systemic autoimmune disease by the stimulation of apoptosispromoting receptor Fas with anti-Fas mAb. Int Immunol 1997, 9: 1793-1799.
70. Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S, et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000; 12: 555562.
71. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: Targeting and activation of death receptors. Cytokine Growth Factor Rev 2005; 16: 55-76.
72. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
73. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003; 23: 1428-1440.
74. Greaney P, Nahimana A, Lagopoulos L, Etter AL, Aubry D, Attinger A, et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res 2006; 30: 415-426.
75. Dupuis, M., Greaney, P., Duchosal, M. Method for ex vivo purging in autologous transplantation. WO2006037762 (2006).
76. Pincelli, C., Marconi, A. Remedies for pemphigus containing anti Fas ligand antibodies. WO2009074339 (2009).
77. Martin-Villalba, A., Letellier, E., Sancho-Martinez, I. Use of CD95 inhibitors for the treatment of inflammatory disorders. WO2010006772 (2010).
78. Belka, C., Herbert, J. Methods and compositions for preventing radiation-induced pneumonities. US20090196868 (2009).
79. Martin-Villalba, A., Kleber, S., Wiestler, B., Krammer, P., Herold- Mende, C. Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo. WO2008080623 (2008).
80. Martin-Villalba, A., Krammer, P., Demjen, D. Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries. US20060234968 (2006).
81. Martin-Villalba, A., Schregelmann, N., Letellier, E., Kleber, S., Klussmann, S. The death receptor CD95 controlsneurogenesis of adult neural stem cells in vivo and in vitro. WO2008034608 (2008).
82. Krammer, P., Martin-Villalba, A. Combination of compounds that inhibit the biological effects of TNF-alpha and CD95 in a medicament. US2003082180 (2003).
83. Pluenneke, J., Connor, T. Inhibition of Fas signalling. US20030170244 (2003).
84. Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14: 53-66.
85. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature 2010; 465: 492-496.
86. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008; 13: 235-248.
87. Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 2004; 10: 389-395.
88. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010; 32: 240-252.
89. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D, et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237: 159-173.
90. Sheikh MS, Fornace, AJ Jr. Death and decoy receptors and p53- mediated apoptosis. Leukemia 2000; 14: 1509-1513.
91. Secchiero P, Zauli G. Tumor-necrosis-factor-related apoptosisinducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008; 15: 42-48.
92. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006; 17: 245-257.
93. Wei W, Wang D, Shi J, Xiang Y, Zhang Y, Liu S, et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4- mediated RhoGTPase pathway. Mol Immunol 2010; 47: 2475-2484.
94. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 25: 7434-7439.
95. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010; 138: 2357-2367.
96. Ahn KS, Sethi G, Chao TH, Neuteboom ST, Chaturvedi MM, Palladino M, et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 2007; 110: 2286-2295.
97. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007; 67: 2247-2255.
98. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102: 303-310.
99. Palacios C, Yerbes R, Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006; 66: 8858-8869.
100. Akasaki Y, Liu G, Matundan HH, Ng H, Yuan X, Zeng Z, et al. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 2006; 281: 6165-6174.
101. Ivanov VN, Hei TK. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAILR1/ R2 surface levels and downregulation of cFLIP expression. Exp Cell Res 2006; 312: 3418-4120.
102. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005; 106: 3917-3925.
103. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, et al. The lkylphospholipid perifosine induces apoptosis of human lung ancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6: 2029-2038.
104. Chen Y, Xu J, Jhala N, Pawar P, Zhu ZB, Ma L, et al. Fasmediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006; 169: 1833-1842.
105. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001; 276: 6893-6896.
106. Suhara T, Mano T, Oliveira BE, Walsh K. Phosphatidylinositol 3- kinase/Akt signaling controls endothelial cell sensitivity to Fasmediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res 2001; 89: 13-19.
107. Morinobu A, Wang B, Liu J, Yoshiya S, Kurosaka M, Kumagai S. Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2006; 33: 1052-1060.
108. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006; 15: 227-2230.
109. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo- 2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64: 2580-2589.
110. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102: 652-658.
111. Yang BF, Xiao C, Roa WH, Krammer PH, Hao C. Calcium/calmodulin-dependent protein kinase II regulation of c- FLIP expression and phosphorylation in modulation of Fasmediated signaling in malignant glioma cells. J Biol Chem 2003; 278: 7043-7050.
112. Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, et al. Induction of apoptosis in 9-nitrocamptothecintreated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res 2001; 61: 7148-7154.
113. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. Cellular FLICEinhibitory protein down-regulation contributes to celecoxibinduced apoptosis in human lung cancer cells. Cancer Res 2006; 66: 11115-11119.
114. Natoni F, Diolordi L, Santoni C, Gilardini Montani MS. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 2005; 1745: 318-329.
115. Platzbecker U, Ward JL, Deeg HJ. Chelerythrin activates caspase- 8, downregulates FLIP long and short, and overcomes resistance to tumour necrosis factor-related apoptosis-inducing ligand in KG1a cells. Br J Haematol 2003; 122: 489-497.
116. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002; 100: 2965-2972.
117. Schlapbach R, Spanaus KS, Malipiero U, Lens S, Tasinato A, Tschopp J, et al. TGF-beta induces the expression of the FLICEinhibitory protein and inhibits Fas-mediated apoptosis of microglia. Eur J Immunol 2000; 30: 3680-3688.
118. Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fasassociated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000; 60: 3947-3956.
119. Wang Q, Wang X, Zhou Y, Evers Bm. PKCdelta-mediated regulation of FLIP expression in human colon cancer cells. Int J Cancer 2006; 118: 326-334.
120. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNFalpha-induced apoptosis through the down-regulation of NFkappaB- dependent antiapoptotic gene products: Role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol 2007; 178: 2507-2516.
121. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007; 109: 2727-2735.
122. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281: 5612-5622.
123. Takada Y, Murakami A, Aggarwal BB. Zerumbone abolishes NFkappaB and IkappaBalpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 2005; 24: 6957-6969.
124. Ichikawa H, Takada Y, Murakami A, Aggarwal BB. Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NFkappa B-regulated gene products. J Immunol 2005; 174: 7383-7392.
125. Takada Y, Kobayashi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaBregulated antiapoptotic and metastatic gene expression, upregulating apoptosis, and inhibiting invasion. J Biol Chem 2005; 280: 17203-17212.
126. Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and upregulation of apoptosis. J Biol Chem 2004; 279: 26287-26299.
127. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007; 178: 1923-1930.
128. Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, et al. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res 2006; 66: 2367-2375.
129. Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med 2002; 8: 725-732.
130. Davidson SM, Stephanou A, Latchman DS. FLIP protects cardiomyocytes from apoptosis induced by simulated ischemia/reoxygenation, as demonstrated by short hairpin-induced (shRNA) silencing of FLIP mRNA. J Mol Cell Cardiol 2003; 35: 1359-1364.
131. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, et al. C-FLIP mediates resistance of Hodgkin/Reed- Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199: 1041-1052.
132. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAILinduced apoptosis. Cell Death Differ 2004; 11: 915-923.
133. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICElike inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004; 23: 6997-7004.
134. Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004; 23: 7753-7760.
135. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosisinducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004; 64: 7086-7091.
136. Watanabe K, Okamoto K, Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005; 12: 10-18.
137. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005; 105: 2510-2518.
138. Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005; 280: 19401-19409.
139. Dolcet X, Llobet D, Pallares J, Rue M, Comella JX, Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005; 85: 885-894.
140. Hashimoto M, Nakajima-Shimada J, Aoki T. Trypanosoma cruzi posttranscriptionally up-regulates and exploits cellular FLIP for inhibition of death-inducing signal. Mol Biol Cell 2005; 16: 3521-3528.
141. Longley DB, Wilson TR, McEwan M, Allen WJ, McDermott U, Galligan L, et al. C-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-848.
142. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. C-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007; 67: 5754-5762.
143. Rogers KM, Thomas M, Galligan L, Wilson TR, Allen WL, Sakai H, et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 2007; 6: 1544-1551.
144. Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Drakos E, et al. C-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 2006; 107: 2544-2547.
145. Okamoto K, Fujisawa J, Reth M, Yonehara S. Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NFkappaB. Genes Cells 2006; 11: 177-191.
146. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C, et al. HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006; 107: 3933-3939.
147. Flahaut M, Muhlethaler-Mottet A, Auderset K, Bourloud KB, Meier R, Popovic MB, et al. Persistent inhibition of FLIP(L) expression by lentiviral small hairpin RNA delivery restores deathreceptor-induced apoptosis in neuroblastoma cells. Apoptosis 2006; 11: 255-263.
148. Song JH, Bellail A, Tse MC, Yong VW, Hao C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci 2006; 26: 3299-3308.
149. Saito K, Meyer K, Warner R, Basu A, Ray RB, Ray R. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006; 80: 4372-4379.
150. Palao G, Santiago B, Galindo M, Paya M, Ramirez JC, Pablos JL. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis Rheum 2004; 50: 2803-2810.
151. Palao G, Santiago B, Galindo MA, Rullas JN, Alcami J, Ramirez JC, et al. Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum 2006; 54: 1473-1481.
152. Maedler K, Schumann DM, Sauter N, Ellingsgaard H, Bosco D, Baertschiger R, et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006; 55: 2713-2722.
153. Shim E, Lee YS, Kim HY, Jeoung D. Down-regulation of c-FLIP increases reactive oxygen species, induces phosphorylation of serine/threonine kinase Akt, and impairs motility of cancer cells. Biotechnol Lett 2007; 29: 141-147.
154. Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 2007; 102: 442-452.
155. Fandy TE, Ross DD, Gore SD, Srivastava RK. Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL. Cancer Chemother Pharmacol 2007; 60: 313-319.
156. Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA, Filmus J, et al. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst 2007; 99: 811-822.
157. Nakajima A, Kojima Y, Nakayama M, Yagita H, Okumura K, Nakano H. Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells. Oncogene 2008; 27: 76-84.
158. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67: 4981-4988.
159. Lane D, Robert V, Grondin R, Rancourt C, Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121: 1227-1237.
160. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, et al. Activated human NK and CD8+ T cells express both TNFrelated apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104: 2418-2424.
161. Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva A, et al. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 2009; 14: 778-787.
162. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773-782.
163. Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, et al. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 2009; 48: 2180-2191.
164. Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A, et al. DR4-selective tumor necrosis factor-related apoptosisinducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008; 283: 20560-20568.
165. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. Designed tumor necrosis factor-related apoptosisinducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006; 103: 8634-8639.